EBITDA Margin % is calculated as EBITDA divided by its Revenue. ADDvise Group AB's EBITDA for the
three
months ended in Mar. 2026 was €5.5 Mil. ADDvise Group AB's Revenue for the
three
months ended in Mar. 2026 was €33.2 Mil. Therefore, ADDvise Group AB's EBITDA margin for the quarter that ended in Mar. 2026 was 16.62%.
ADDvise Group AB (FRA:Q3I) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
ADDvise Group AB EBITDA Margin % Related Terms
ADDvise Group AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for ADDvise Group AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:Q3I vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, ADDvise Group AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADDvise Group AB EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ADDvise Group AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where ADDvise Group AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADDvise Group AB (FRA:Q3I) has a EBITDA Margin % of 16.62% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ADDvise Group AB and its competitors. This is 49% above median its historical median of 11.16. Over the past decade, ADDvise Group AB's EBITDA Margin % has ranged from 3.07 to 26.92.
Is ADDvise Group AB's EBITDA Margin % too high?
ADDvise Group AB's current EBITDA Margin % of 16.62% is 49% above median its 10-year median of 11.16. Over the past 10 years, this metric has ranged from a low of 3.07 to a high of 26.92. The Medical Devices & Instruments industry median EBITDA Margin % is 7.44. ADDvise Group AB's value of 16.62% is 123.4% above this industry median. Overall, ADDvise Group AB has a GF Score™ of 84/100, reflecting its overall financial health beyond just this single metric.
How does ADDvise Group AB's EBITDA Margin % compare to ISRG and BDX?
ADDvise Group AB's EBITDA Margin % of 16.62% can be compared against companies in the Medical Devices & Instruments industry. The industry median EBITDA Margin % is 7.44. ADDvise Group AB's value of 16.62% is 123.4% above this benchmark. Historically, ADDvise Group AB's own EBITDA Margin % has ranged from 3.07 to 26.92 over the past decade. While the company's 10-year median is 11.16 vs. the industry median of 7.44, ADDvise Group AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.44, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ADDvise Group AB's current EBITDA Margin % of 16.62% is 123.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ADDvise Group AB and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ADDvise Group AB's current EBITDA Margin % is 16.62%, which is 49% above median its own 10-year median of 11.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADDvise Group AB stock overvalued right now?
ADDvise Group AB (FRA:Q3I) has a current EBITDA Margin % of 16.62%. The stock's GF Value™ is €0.28, compared to a current price of €0.14 — trading 49.2% below its estimated fair value. The current EBITDA Margin % is 16.62%, which is 49% above median its 10-year median of 11.16 and 123.4% above the Medical Devices & Instruments industry median of 7.44. ADDvise Group AB's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For ADDvise Group AB (FRA:Q3I), the current EBITDA Margin % is 16.62% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADDvise Group AB (FRA:Q3I) Overvalued in 2026?
Based on GuruFocus' analysis, ADDvise Group AB stock appears to be undervalued.
The current stock price of €0.14 is trading 49.2% below its estimated GF Value™ of €0.28.
Key valuation signals for FRA:Q3I:
EBITDA Margin %: 16.62% (49% above median its 10-year median of 11.16)
GF Value™: €0.28 vs. price of €0.14 (49.2% below fair value)
Industry Position: 123.4% above the Medical Devices & Instruments median
No single metric tells the full story. See the FRA:Q3I stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADDvise Group AB e is an international life science company. Operating a decentralized ownership model, in which company develop and acquire high quality companies within the business areas Lab and Healthcare.
84GF Score
Get the complete analysis for FRA:Q3I
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:Q3I has been successfully added to your 
